BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1
*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1
†BRILIQUE (ticagrelor) 90mg twice daily in combination with acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment
BRILIQUE (ticagrelor) can be taken with or without food.1
BRILIQUE (ticagrelor) is indicated for use either whole, or as crushed tablets, unlike the thienopyridines.1,2,3
BRILIQUE (ticagrelor) as crushed tablets mixed in water, can be given orally immediately or administered through a nasogastric tube.
The glass should be rinsed with a further half glass of water and the contents drunk immediately. It is important to flush the nasogastric tube through with water after administration of the mixture.
Bioavailability of BRILIQUE (ticagrelor)
BRILIQUE (ticagrelor) as crushed tablets mixed in water has a comparable bioavailability to whole tablets with regards to AUC and Cmax for BRILIQUE (ticagrelor) and the active metabolite. Initial exposure (0.5 and 1 hour post-dose) from crushed BRILIQUE (ticagrelor) tablets mixed in water was higher compared to whole tablets, with a generally identical concentration profile thereafter (2 to 48 hours).1
In an open-label cross over study of 36 healthy subjects, administration of crushed ticagrelor 90 mg tablets (orally orvia nasograstric tube) resulted in higher ticagrelor plasma concentrations at early timepoints (0.5 and 1 h) vs. whole tablets.11